Men suffering from category <scp>III</scp> chronic prostatitis may benefit from N‐acetylcysteine as an adjunct to alpha‐blockers

Yaryari, Amir‐Mohammad; Mousavi-Bahar, Seyed Habibollah; Amirhassani, Shahriar; Bagheri, Maryam; Mohammadi, Younes; Mehrpooya, Maryam

doi:10.1111/luts.12425

Cited by 5 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We followed three glass test as this yielded good result and was cost effective. According to Yaryari AM et.al N N-acetylcysteine treatment bene ts men with category III CP [13]. Diclofenac Na was well tolerated by 88.7% of the patients.…”

Section: Discussionmentioning

confidence: 97%

Chronic bacterial prostatitis treatment using quadruple regimen therapy: a preliminary prospective observational study

Hameed,

Anwaar,

mannan

et al. 2024

Preprint

View full text Add to dashboard Cite

Background This study explored the data collected from 27 patients who underwent a new treatment combination of drugs using quadruple regimen therapy with tadafil 5 mg, N-acetylcysteine 200 mg, diclofenac sodium, and a targeted antibiotic for chronic bacterial prostatitis treatment. Methods Twenty-seven Pakistani patients underwent a three-glass test. Those who tested positive received quadruple therapy, while negative cases were treated with triple therapy minus antibiotics, using a gradual tapering off technique for a duration of 20 weeks, and followed for 1 year to observe the recurrence of the disease. Patients were evaluated for international prostatic score, improvement in quality of life, uroflowmeteric studies, improvement in symptoms, and disease recurrence. Chi-square test was used to analyze the data, and p value < 0.05 was considered significant. Results This study yielded favorable results with significant improvements in symptoms, IPSS score, quality of life, urinary flow rate, and post-micturition residual volume (p < 0.05). Of the 19 participants with positive three-glass tests, 14/19 (73%) saw a complete resolution of symptoms; however, three (26%) had a reemergence six months later. The remaining eight patients (29%) who tested negative did not show the same level of effectiveness as the positive cases, but still observed improvements in quality of life and IPPS score (P < 0.05). However, their symptoms were not fully resolved. Conclusions Our study resulted in significant improvement in the patients’ IPSS score, disease symptoms and quality of life after 20 weeks of therapy, with five visits each. All medications were gradually tapered.

show abstract

Section: Discussionmentioning

confidence: 97%

Chronic bacterial prostatitis treatment using quadruple regimen therapy: a preliminary prospective observational study

Hameed,

Anwaar,

mannan

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Moreover, patients with CP/CPPS can be treated with low-dose daily antibiotics, alpha-1 antagonists, 5-alpha reductase inhibitors, anti-inflammatory agents, phytotherapy and neuromodulatory agents. N-acetylcysteine could be useful as an adjunct to alpha-blockers, too [ 32 ]. Nevertheless, a recent review highlighted how pharmacological treatments had little evidence supporting their efficacy in CP/CPPS [ 33 ].…”

Section: Introductionmentioning

confidence: 99%

Chronic Prostatitis/Chronic Pain Pelvic Syndrome and Male Infertility

Graziani,

Grande,

Martin

et al. 2023

Life

View full text Add to dashboard Cite

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is defined as urologic pain or discomfort in the pelvic region, associated with urinary symptoms and/or sexual dysfunction, lasting for at least 3 of the previous 6 months. The rate of symptoms related to prostatitis has a mean prevalence of 8–8.2%. CP/CPPS is most frequent in men younger than 50 years, among whom it is the most common urologic diagnosis. In the last decades, many studies have been published on CP/CPPS and its association with male infertility. The pathophysiologic relation between CP/CPPS and male infertility involves several aspects, which are not well studied yet. A reduction in semen parameters has been demonstrated in patients with CP/CPPS, and several mechanisms have been proposed to represent putative pathophysiological links between CP/CPPS and infertility, including male accessory gland inflammation, metabolic syndrome, inflammatory bowel disease, HPV co-infection and autoimmunity. In light of this evidence, a multidisciplinary approach is advocated for patients with known CP/CPPS, and particular attention is needed for male patients of infertile couples in order to evaluate male accessory glands correctly. In addition, it is advisable that future studies dealing with the treatment of CP/CPPS take into consideration all the different pathophysiological aspects implicated.

show abstract

“…

In both diseases, there is a chronic inflammatory process in which pro-inflammatory cytokines and oxygen and nitrogen reactive species (ROS/RNS) play an important role (6-10). Furthermore, there are studies in the literature that have confirmed the therapeutic efficacy of the use of antioxidant substances in both diseases (10)(11)(12)(13)(14)(15). We also know that pro-inflammatory cytokines, Tumor Necrosis Factor (TNF), and interleukin 1 and 6 (IL-1 and IL-6) are present at high levels in the inflammatory process of PD and chronic prostatitis (CP) (6, 7).

…”

mentioning

confidence: 99%

Chronic prostatitis as possible risk factor for Peyronie's disease: Psychological, sexual and prostatitis-like symptoms in patients with PD

Paulis¹,

Paulis²

2023

Arch Ital Urol Androl

View full text Add to dashboard Cite

Objective: This study aims to investigate a possible relationship between chronic prostatitis (CP) and Peyronie's disease (PD) and to characterize the psychological profile of patients suffering from PD, with or without concomitant CP. Methods: We included 539 patients with PD, of which 200 were found to have underlying CP. As a comparator population, we selected 2201 patients without PD, referring to our tertiary care clinic. In this population, we detected 384 subjects with CP. All 539 PD patients underwent photographic documentation of the penile deformation, and dynamic penile eco-color Doppler with plaque and volume measurements and answered the following questionnaires: the Generalized Anxiety Disorder-7, the Patient Health Questionnaire-9, the Visual Analog Scale for penile pain measurements, the International Index of Erectile Function (IIEF), and the NIH-Chronic Prostatitis Symptom Index. Results: The overall prevalence of chronic prostatitis in PD patients was 37.1% compared to a prevalence of 17.4% in the non-PD control population (OR = 2.79 and p < 0.0001). The severity of CP symptom total scores (NIH-CPSI) correlated significantly with the severity of erectile dysfunction (p < 0.0001). Significant anxiety was present in 89.2% of PD patients and it is more prevalent in PD patients with CP than in PD patients without CP (93.0% vs. 87.0%, respectively; p = 0.0434). Significant depression was detected in 57.1% of PD patients and it is more prevalent in PD patients with CP than in PD patients without CP (64.0% vs. 53.09%, respectively; p = 0.0173). Conclusion: Chronic prostatitis (CP) and Peyronie's disease (PD) are frequently associated. Our results demonstrate the strong impact of chronic prostatitis on the mental status of PD patients. Anxiety and depression were significantly more pronounced in PD patients with CP than in PD patients without CP.

show abstract

Men suffering from category III chronic prostatitis may benefit from N‐acetylcysteine as an adjunct to alpha‐blockers

Cited by 5 publications

References 41 publications

Chronic bacterial prostatitis treatment using quadruple regimen therapy: a preliminary prospective observational study

Chronic bacterial prostatitis treatment using quadruple regimen therapy: a preliminary prospective observational study

Chronic Prostatitis/Chronic Pain Pelvic Syndrome and Male Infertility

Chronic prostatitis as possible risk factor for Peyronie's disease: Psychological, sexual and prostatitis-like symptoms in patients with PD

Contact Info

Product

Resources

About